Press release: closing of Lovaltech seed financing round

Funding has been allocated to conduct Phase 1 and 2 clinical trials of LVT-001.

Lovaltech has closed a seed funding round of €6.8 million. This comprises €1.5 million in equity and €5.3 million in non-dilutive financing from Bpifrance, which was obtained through a France 2030 project funding call. The main investors are Da Vinci Labs, a deep-tech incubator based in Touraine, and the Centre-Val de Loire Seed Fund, which is managed by UI Investissement.

This funding will enable the launch of Phase 1 and 2 clinical trials for LVT-001, the first vaccine from our LVT-NEXUS platform.

Designated as “Deeptech” company by Bpifrance, Lovaltech holds an exclusive worldwide licence for the patent on its first vaccine, granted by its original research institutions.

This website use coockies and give you the control on what you want to activate. Accept all Personnalise